RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/18246078http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/18246078http://www.w3.org/2000/01/rdf-schema#comment"Treacher Collins syndrome (TCS) is a congenital disorder of craniofacial development arising from mutations in TCOF1, which encodes the nucleolar phosphoprotein Treacle. Haploinsufficiency of Tcof1 perturbs mature ribosome biogenesis, resulting in stabilization of p53 and the cyclin G1-mediated cell-cycle arrest that underpins the specificity of neuroepithelial apoptosis and neural crest cell hypoplasia characteristic of TCS. Here we show that inhibition of p53 prevents cyclin G1-driven apoptotic elimination of neural crest cells while rescuing the craniofacial abnormalities associated with mutations in Tcof1 and extending life span. These improvements, however, occur independently of the effects on ribosome biogenesis; thus suggesting that it is p53-dependent neuroepithelial apoptosis that is the primary mechanism underlying the pathogenesis of TCS. Our work further implies that neuroepithelial and neural crest cells are particularly sensitive to cellular stress during embryogenesis and that suppression of p53 function provides an attractive avenue for possible clinical prevention of TCS craniofacial birth defects and possibly those of other neurocristopathies."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.org/dc/terms/identifier"doi:10.1038/nm1725"xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Dixon J."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Du C."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Dixon M.J."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Aoto K."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Jones N.C."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Gaudenz K."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Trainor P.A."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Sakai D."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Glynn E.F."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Rey J.P."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Ellington L."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/author"Lynn M.L."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/date"2008"xsd:gYear
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/name"Nat Med"xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/pages"125-133"xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/title"Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function."xsd:string
http://purl.uniprot.org/citations/18246078http://purl.uniprot.org/core/volume"14"xsd:string
http://purl.uniprot.org/citations/18246078http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/18246078
http://purl.uniprot.org/citations/18246078http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/18246078
http://purl.uniprot.org/uniprot/#_A0A0A6YWE0-mappedCitation-18246078http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18246078
http://purl.uniprot.org/uniprot/#_D3YZ35-mappedCitation-18246078http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18246078
http://purl.uniprot.org/uniprot/#_P70677-mappedCitation-18246078http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18246078